References
- Turesson I, Velez R, Kristinsson SY, . Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28:830–834.
- Kyle RA, Gertz MA, Witzig TE, . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.
- Madan S, Kumar S. Review: extramedullary disease in multiple myeloma. Clin Adv Hematol Oncol 2009;7:802–804.
- Short KD, Rajkumar SV, Larson D, . Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906–908.
- Perez-Persona E, Vidriales MB, Mateo G, . New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586–2592.
- Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010;149:334–351.
- Paiva B, Almeida J, Perez-Andres M, . Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010;78:239–252.
- Rawstron AC, Orfao A, Beksac M, . Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431–438.
- Lin P, Owens R, Tricot G, . FLow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482–488.
- Lund FE, Cockayne DA, Randall TD, . CD38: a new paradigm in lymphocyte activation and signal transduction. Immunol Rev 1998;161:79–93.
- Dianzani U, Funaro A, DiFranco D, . Interaction between endothelium and CD4 + CD45RA + lymphocytes. Role of the human CD38 molecule. J Immunol 1994;153:952–959.
- de Weers M, Tai YT, van der Veer MS, . Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840–1848.
- Boll M, Parkins E, O'Connor SJ, . Extramedullary plasmacytoma are characterized by a “myeloma-like” immunophenotype and genotype and occult bone marrow involvement. Br J Haematol 2010;151:525–527.
- Cao W, Goolsby CL, Nelson BP, . Instability of immunophenotype in plasma cell myeloma. Am J Clin Pathol 2008;129:926–933.
- Ngo NT, Brodie C, Giles C, . The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome. J Clin Pathol 2009;62:1009–1015.
- Roshal M, Fromm JR, Winter S, . Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytometry B Clin Cytom 2010;78:139–146.